All In Biotech

Drug Trial Radar · NCT07811882

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Oct 10, 2025

Primary completion

Jun 17, 2026

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

  • KAE609 (Cipargamin)Drug

    oral KAE609 (Cipargamin)

  • SoC (Coartem)Drug

    SoC (Coartem)

  • INE963Drug

    oral INE963

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)Time frame: Day 29

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Banfora, Burkina Faso

  • Novartis Investigative Site

    Nanoro, Burkina Faso

  • Novartis Investigative Site

    Abidjan, Côte d’Ivoire

  • Novartis Investigative Site

    Azaguié, Côte d’Ivoire

  • Novartis Investigative Site

    Lambaréné, Gabon

  • Novartis Investigative Site

    Libreville, Gabon

  • Novartis Investigative Site

    Kintampo, Ghana

  • Novartis Investigative Site

    Navrongo, Ghana

  • Novartis Investigative Site

    Ahero, Kenya

  • Novartis Investigative Site

    Kisumu, Kenya

  • Novartis Investigative Site

    Kigali, Rwanda

  • Novartis Investigative Site

    Kampala, Uganda

  • Novartis Investigative Site

    Tororo, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.